Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025Business Wire • 12/08/25
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?Zacks Investment Research • 12/08/25
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?Zacks Investment Research • 12/05/25
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)Business Wire • 12/05/25
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/04/25
A delayed clinical trial actually boosted Bristol Myers Squibb's stock. Here's why.Market Watch • 12/03/25
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After IrregularitiesBenzinga • 12/03/25
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers SquibbBusiness Wire • 12/03/25
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's DiseaseBusiness Wire • 12/03/25
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rulesReuters • 12/01/25
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation PortfolioBusiness Wire • 12/01/25
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)Zacks Investment Research • 11/27/25
Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare ConferenceBusiness Wire • 11/26/25
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy BreyanziZacks Investment Research • 11/25/25